陽光城(000671.SZ):陽光智博發行H股並於香港聯交所主板上市的申請材料獲中證監受理
格隆匯6月2日丨陽光城(000671.SZ)公佈,此前披露,公司第十屆董事局第十八次會議及2020年年度股東大會審議通過了公司控股子公司上海陽光智博生活服務集團股份有限公司(“陽光智博”)首次公開發行境外上市外資股(H股)並於香港聯交所主板上市等相關事項。
公司於2021年6月2日收到中國證監會出具的行政許可申請受理單(受理序號:211177)。中國證監會決定對陽光智博提交的境外首次公開發行股份的行政許可申請予以受理。
陽光智博境外上市事項尚需取得中國證監會、香港聯交所及其他有關監管機構的核準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.